Larger clinical cohort studies and prospective trials are needed to verify the direct link between how an mRNA is regulated and linked to breast cancer recurrence to the molecular subtype of breast cancer (such as HER2+, luminal, etc.). This evidence concerns the gene ERBB2 and breast carcinoma.